Harvard Apparatus Regenerative Technology

Website

Harvard Apparatus Regenerative Technology, Inc.

2 Investors
Regenerative Medicine and Biotechnology
HOLLISTON, MA

Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company that develops regenerative-medicine treatments for disorders of the gastrointestinal system and airways. Its core focus is the proprietary Cellspan™ technology platform, which uses a patient's own stem cells to regenerate and restore function to damaged organs. The company also generates secondary revenue from selling consumer health products in Asia.

Products & Team

Cellspan™ Esophageal Implant

Bioengineered Organ ImplantSeed

The Cellspan™ Esophageal Implant is a bioengineered implant designed to treat conditions of the esophagus resulting from cancer, trauma, birth defects such as esophageal atresia, or damage from chemoradiation. It is a 'living tube' created by seeding a patient's own stem cells onto a proprietary, biocompatible scaffold that mimics the dimensions of the damaged organ, designed to trigger the body's natural healing processes to regenerate the tissue.

Value Proposition

It addresses the critical need for a functional organ replacement for patients suffering from end-stage esophageal disease, potentially avoiding the complications associated with traditional reconstructive surgery or synthetic implants.

Pain Points

Patients face life-altering conditions caused by the removal or severe damage of their esophagus or airways, for which current treatment options are limited, highly invasive, or carry significant risks and complications.

Utilizes a patient's own autologous stem cells to minimize rejection riskEmploys a proprietary biocompatible scaffoldDesigned to trigger the body's natural tissue regeneration processesAims to restore organ function for esophageal disorders
Industry
Biotechnology
Primary business sector
Founded
2025
Year established
Location
HOLLISTON, MA
Primary headquarters

Funding History

Total Raised:
$2.0M
E

Equity Offering

Closed
July 2025
$2.0M
Raised
Use of Proceeds
Some of the proceeds may be used for working capital and other general corporate purposes, which may include the payment of salaries and other fees to those listed in Item 3.
Progress
100%
Raised
$2.0M
Target
$2.0M
#000143774925022651